Low Dose Naltrexone (LDN)
According to the Low Dose Naltrexone home page [LDN], LDN has been seen to benefit
Scleroderma, which is considered to be an autoimmune disease.
[Frech2011 🕮 ] reports a 3-case series in which LDN gave significant improvement in pruritus
associated with systemic sclerosis.
Dr. Weyrich has been trained to use Low Dose Naltrexone (LDN).
However, Dr. Weyrich has not treated any cases of Scleroderma
with LDN.
Please see What is Low Dose Naltrexone?
for more information.
Immune System Balancing
[McCulley2018, pp 28, 62, 89] reports that scleroderma may be a
TH2-dominant, systemic,
autoimmune disorder, and proposes an approach to treating this disease, which should be
supervised by a properly trained medical professional.
Dr. Weyrich has considerable interest in this topic, but has
not treated any cases of scleroderma
with Immune System Balancing.
Please see What is Immune System Balancing?
for more information.
Neurotransmitter Balancing
Neuro Research [Hinz2015] reports that
chronic diseases such as Systemic Sclerosis
can be benefited by balancing neurotransmitter levels in the body.
Dr. Weyrich has been trained in neurotransmitter balancing protocols, but has not treated
Systemic Sclerosis, Scleroderma, or Morphea using this technique.
Please see What is Neurotransmitter Balancing?
for more information.